GSK 257049

ApprovedBiologic

GSK

GSK 257049 is one of 323 biologic programs targeting Lung Cancer. It is currently in Approved.

Indications

Total Trials

Active Trials

322

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

MalariaActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

ImmunodeficiencyActive, not recruiting

Acute Otitis MediaActive, not recruiting

Breast CancerActive, not recruiting

MelanomaActive, not recruiting

Hepatitis BActive, not recruiting

InfluenzaActive, not recruiting

TuberculosisActive, not recruiting

Lung CancerPhase 2

Active, not recruiting

MalariaPhase 2

Active, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 3

Active, not recruiting

ImmunodeficiencyApproved

Active, not recruiting

Acute Otitis MediaPhase 3

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

MelanomaPhase 3

Active, not recruiting

Hepatitis BPhase 2

Active, not recruiting

InfluenzaPhase 3

Active, not recruiting

TuberculosisPhase 2

Active, not recruiting

Showing 10 of 13 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

GSK 257049

GSK

Approved

1 2

Trodelvy

Gilead

Preclinical

37 3

Tecentriq

Roche

Preclinical

36 4

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 5

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 6

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 7

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 8

Beta Blocker

WWeill Medical College of Cornell University

Preclinical

1 9

Lipegfilgrastim

Merck & Co.

Preclinical

1 10

Ibrance

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Influenza27 trials

Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Children

Terminated· GSK logo

GSK·Phase 3·NCT01014091·60 enrolled

Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older

Completed· GSK logo

GSK·Phase 3·NCT00765076·192 enrolled

Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older

Completed· GSK logo

GSK·Phase 3·NCT00753272·43,695 enrolled

Show 24 more trials

Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure

Withdrawn· GSK logo

GSK·Phase 2·NCT01045564

Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children

Completed· GSK logo

GSK·Phase 3·NCT00980005·2,116 enrolled

Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults

Completed· GSK logo

GSK·Phase 1·NCT01059617·133 enrolled

Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children

Terminated· GSK logo

GSK·Phase 2·NCT01195779·4 enrolled

Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing Processes

Completed· GSK logo

GSK·Phase 3·NCT00992511·300 enrolled

Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults.

Completed· GSK logo

GSK·Phase 1·NCT00714285·420 enrolled

Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children

Completed· GSK logo

GSK·Phase 2·NCT01323946·113 enrolled

Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults

Completed· GSK logo

GSK·Phase 2·NCT00951041·130 enrolled

Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and Over

Completed· GSK logo

GSK·Phase 2·NCT00532298·1,596 enrolled

Evaluation of Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults

Completed· GSK logo

GSK·Phase 2·NCT00538213·133 enrolled

Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly

Completed· GSK logo

GSK·Phase 3·NCT00938392·726 enrolled

Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control

Completed· GSK logo

GSK·Phase 2·NCT00778895·390 enrolled

Study to Evaluate Immunogenicity & Safety of an Investigational Influenza Vaccine in Adults

Completed· GSK logo

GSK·Phase 3·NCT00975884·312 enrolled

Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine

Completed· GSK logo

GSK·Phase 1·NCT01657526·48 enrolled

Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults

Completed· GSK logo

GSK·Phase 3·NCT00968539·130 enrolled

Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old

Completed· GSK logo

GSK·Phase 1·NCT01236040·521 enrolled

Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults

Completed· GSK logo

GSK·Phase 2·NCT00538473·68 enrolled

Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years Old

Completed· GSK logo

GSK·Phase 2·NCT01161160·209 enrolled

Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People

Completed· GSK logo

GSK·Phase 3·NCT00992784·370 enrolled

Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults

Completed· GSK logo

GSK·Phase 3·NCT00968526·240 enrolled

Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly

Completed· GSK logo

GSK·Phase 3·NCT00772889·971 enrolled

Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older

Completed· GSK logo

GSK·Phase 3·NCT00760617·526 enrolled

Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults

Completed· GSK logo

GSK·Phase 3·NCT00529516·1,252 enrolled

Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children

Completed· GSK logo

GSK·Phase 3·NCT00972517·245 enrolled

Papilloma6 trials

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects

Completed· GSK logo

GSK·Phase 3·NCT00426361·751 enrolled

Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls

Completed· GSK logo

GSK·Phase 3·NCT01381575·1,447 enrolled

Human Papillomavirus Vaccine Safety & Immunogenicity Trial in Healthy Young Adult Women With HPV Vaccine (GSK1674330A)

Completed· GSK logo

GSK·Phase 1·NCT00478621·540 enrolled

Show 3 more trials

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US

Completed· GSK logo

GSK·Phase 3·NCT00799825·346 enrolled

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

Completed· GSK logo

GSK·Phase 3·NCT00423046·1,106 enrolled

Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine

Completed· GSK logo

GSK·Phase 3·NCT00316706·1,245 enrolled

Malaria6 trials

Characterisation of the Immune Responses of 2 Experimental Malaria Vaccines

Completed· GSK logo

GSK·Phase 2·NCT00443131·36 enrolled

Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants

Completed· GSK logo

GSK·Phase 2·NCT01231503·480 enrolled

Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults

Completed· GSK logo

GSK·Phase 2·NCT01366534·67 enrolled

Show 3 more trials

Efficacy of RTS,S/AS01 Vaccine Against Episodes of Malaria Due to P. Falciparum Infection in Children.

Completed· GSK logo

GSK·Phase 2·NCT00380393·894 enrolled

Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children

Completed· GSK logo

GSK·Phase 3·NCT01148459·200 enrolled

Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen

Completed· GSK logo

GSK·Phase 2·NCT00436007·511 enrolled

Immunogenicity6 trials

Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age

Completed· GSK logo

GSK·Phase 2·NCT00861744·1,259 enrolled

Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule

Completed· GSK logo

GSK·Phase 3·NCT00307034·351 enrolled

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years

Completed· GSK logo

GSK·Phase 2·NCT00771615·469 enrolled

Show 3 more trials

Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds

Completed· GSK logo

GSK·Phase 2·NCT00892775·501 enrolled

Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years

Completed· GSK logo

GSK·Phase 3·NCT00871117·478 enrolled

Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects

Completed· GSK logo

GSK·Phase 1·NCT00435396·40 enrolled

Tuberculosis4 trials

Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults

Completed· GSK logo

GSK·Phase 2·NCT01755598·3,575 enrolled

Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342

Completed· GSK logo

GSK·Phase 2·NCT01669096·20 enrolled

Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) to Healthy Adults

Completed· GSK logo

GSK·Phase 2·NCT00621322·180 enrolled

Show 1 more trial

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease

Terminated· GSK logo

GSK·Phase 2·NCT01424501·142 enrolled

21 more indications

Vaccination3 trials

Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™

Completed· GSK logo

GSK·Phase 3·NCT00678301·365 enrolled

Primary Vaccination Course in Children Receiving Pneumococcal Conjugate Vaccine GSK 1024850A or Prevenar™ and Hiberix™

Completed· GSK logo

GSK·Phase 3·NCT00680914·503 enrolled

Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same Vaccine

Completed· GSK logo

GSK·Phase 3·NCT00911144·450 enrolled

Children2 trials

Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children

Completed· GSK logo

GSK·Phase 3·NCT00674583·414 enrolled

Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612

Completed· GSK logo

GSK·Phase 2·NCT00427908·613 enrolled

Diphtheria2 trials

Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults

Completed· GSK logo

GSK·Phase 3·NCT01267058·550 enrolled

Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis®

Completed· GSK logo

GSK·Phase 3·NCT01277705·806 enrolled

Acute otitis media2 trials

COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine

Completed· GSK logo

GSK·Phase 3·NCT00466947·23,802 enrolled

Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A

Completed· GSK logo

GSK·Phase 3·NCT00839254·6,181 enrolled

Rotavirus Vaccine2 trials

Study to Assess the Safety of GSK Biologicals' Liquid Human Rotavirus Vaccine in Healthy Infants

Completed· GSK logo

GSK·Phase 1·NCT01107587·50 enrolled

Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants

Completed· GSK logo

GSK·Phase 3·NCT01171963·3,340 enrolled

Vaccine2 trials

Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants

Completed· GSK logo

GSK·Phase 4·NCT00325156·2,590 enrolled

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

Completed· GSK logo

GSK·Phase 3·NCT00614614·1,558 enrolled

Immunodeficiency1 trial

Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

Completed· GSK logo

GSK·Phase 4·NCT01031069·873 enrolled

Melanoma1 trial

A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor

Terminated· GSK logo

GSK·Phase 3·NCT00796445·1,351 enrolled

Effectiveness1 trial

Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease

Completed· GSK logo

GSK·Phase 3·NCT00861380·41,188 enrolled

Hepatitis B1 trial

Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B Vaccine

Completed· GSK logo

GSK·Phase 2·NCT00805389·713 enrolled

Single Dose1 trial

Single Dose Escalation First Time in Human PK Study

Completed· GSK logo

GSK·Phase 1·NCT00828867·41 enrolled

Chronic Obstructive Pulmonary Disease1 trial

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A

Completed· GSK logo

GSK·Phase 3·NCT01328444·349 enrolled

Herpes Zoster1 trial

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy

Completed· GSK logo

GSK·Phase 3·NCT01798056·237 enrolled

Breast Cancer1 trial

Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive Metastatic Breast Cancer

Completed· GSK logo

GSK·Phase 1·NCT00140738·3 enrolled

Varicella1 trial

Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM

Completed· GSK logo

GSK·Phase 3·NCT00969436·450 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons

Completed· GSK logo

GSK·Phase 2·NCT01218113·191 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age

Completed· GSK logo

GSK·Phase 3·NCT01051661·6,154 enrolled

Immune Response1 trial

Evaluation of the Immune Response of a HIV Candidate Vaccine After Administration of One Chloroquine Dose

Completed· GSK logo

GSK·Phase 2·NCT00972725·28 enrolled

Lung Cancer1 trial

Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery

Completed· GSK logo

GSK·Phase 2·NCT00290355·182 enrolled

Long-term Follow-up1 trial

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Completed· GSK logo

GSK·Phase 1·NCT01092611·190 enrolled

Unspecified1 trial

Post Market Surveillance for Infanrix™

Completed· GSK logo

GSK··NCT00908115·1,258 enrolled

Sources

References

[1]
ClinicalTrials.gov — 77 trial records for GSK 257049. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GSK 257049 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GSK 257049. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: GSK

GSK 257049

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Influenza27 trials

Papilloma6 trials

Malaria6 trials

Immunogenicity6 trials

Tuberculosis4 trials

Vaccination3 trials

Children2 trials

Diphtheria2 trials

Acute otitis media2 trials

Rotavirus Vaccine2 trials

Vaccine2 trials

Immunodeficiency1 trial

Melanoma1 trial

Effectiveness1 trial

Hepatitis B1 trial

Single Dose1 trial

Chronic Obstructive Pulmonary Disease1 trial

Herpes Zoster1 trial

Breast Cancer1 trial

Varicella1 trial

Efficacy and Safety1 trial

Safety and Efficacy1 trial

Immune Response1 trial

Lung Cancer1 trial

Long-term Follow-up1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News